Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Arbutus Biopharma Corp (NQ: ABUS ) 3.870 +0.040 (+1.04%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Arbutus Biopharma Corp < Previous 1 2 3 4 5 6 Next > Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference October 18, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023 October 11, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Small Biotech Promosome Drops Lawsuit Against Pfizer, BioNTech in COVID-19 Vaccine Patent Dispute October 05, 2023 Biotech firm Promosome has agreed to end the lawsuit, which accused the COVID-19 vaccine manufacturers, Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX), of patent infrin Via Benzinga Topics Intellectual Property Lawsuit Exposures COVID-19 Financial Intellectual Property Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended September 11, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus Biopharma Q1 Exceeds Consensus View; Cuts Cash Burn Guidance May 04, 2023 Via Benzinga Recap: Arbutus Biopharma Q1 Earnings May 04, 2023 Via Benzinga Arbutus to Participate in Two Upcoming Investor Conferences September 07, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire 3 Stocks to Buy For the COVID Resurgence September 06, 2023 The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting Via MarketBeat Exposures COVID-19 Product Safety Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update August 03, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus Biopharma's Earnings Outlook May 03, 2023 Via Benzinga Why Arbutus Biopharma Stock Is Sinking Today April 25, 2023 After a strong start to 2023, the virology-focused biopharma company has hit a regulatory speed bump. Via The Motley Fool Why Arbutus Biopharma Stock Is Plunging Today April 25, 2023 Via Benzinga Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update July 20, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors July 12, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus Appoints Two New Executives July 10, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody June 21, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023 June 21, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023 June 07, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus to Present at Jefferies Healthcare Conference May 31, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus to Present at JMP Securities Life Sciences Conference May 09, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus Reports First Quarter 2023 Financial Results and Corporate Update May 04, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023 April 27, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor April 25, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus to Report First Quarter 2023 Financial Results and Provide Corporate Update April 20, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023 April 18, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire US Court Favors Moderna In COVID-19 Vaccine Patent Infringement Case With Arbutus Biopharma April 12, 2023 Via Benzinga Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots April 04, 2023 Via Benzinga Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech April 04, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161 March 16, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research March 14, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.